RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

This casts CX-717 in a very different light. It is not a flawed compound. Rather, for a risk-averse regulatory agency, ADHD was an indication for which extraordinarily high standards were being set.

Ombow follows COR as closely as anyone, and his take is that CX-717 may not be approvable for anything, based on psychiatry's decision:

>>The lead compound, CX717, was rejected by the FDA's Dept. of Psychiatry, leaving in doubt whether it will ever be approved for RD.

If you are right about how the whole thing went down, this inference is too strong, and it is in COR's interest that the ADHD debacle not be misunderstood in this way. The investment community should not have to rely on a phrase in a conference call to understand what happened.